Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient
New Agents in R/R Large Cell Lymphoma: Pola + BR Promising Treatment, Blinatumomab and Lenalidomide Have Limited Efficacy, & Mosunetuzumab Monotherapy Achieves CR in High-Risk Pts
Comments 0
Login to view comments.
Click here to Login
